Info

CELATOR® is a privately held biopharmaceutical company working to develop new and more effective combination therapies to treat cancer. CombiPlexSM/TM, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies. Based on the strength of the CombiPlex technology platform, Celator is positioned to develop a range of products targeting many different forms of cancer. The Company's development program already includes several promising combination therapy product candidates:CPX-1 (Irinotecan HCI-Floxuridine ) is in Phase 2 clinical development as a treatment for colorectal cancer.